ID

31967

Descrizione

Study ID: 106181 Clinical Study ID: B2C106181 Study Title: An open-label, single-arm study to determine the excretion balance and metabolic disposition of [14C]GW642444 administered as a single dose of an oral solution to healthy male volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01286831 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: vilanterol Trade Name: Study Indication: Pulmonary Disease, Chronic Obstructive

Keywords

  1. 09/10/18 09/10/18 -
  2. 09/10/18 09/10/18 - Julian Varghese
  3. 10/10/18 10/10/18 -
  4. 10/10/18 10/10/18 -
  5. 14/12/18 14/12/18 -
Titolare del copyright

GSK group of companies

Caricato su

9 ottobre 2018

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Extension balance and metabolic disposition of vilanterol as a single oral dose

Follow-Up Forms

  1. StudyEvent: ODM
    1. Follow-Up Forms
Physical examination data
Descrizione

Physical examination data

Concomitant medications
Descrizione

Record any changes to the subject's concomitant medications or any new medications taken since the last visit in the appropriate Concomitant Medications section

Tipo di dati

text

Adverse Events
Descrizione

Record details of any new Adverse Events obseved or reported by the subject or any changes to ongoing adverse events in the appropriate NON-Serious Adverse Events/Serious Adverse Events section.

Tipo di dati

text

Physical Examination
Descrizione

Indicate current physical findings by choosing the appropriate box(es) below and if YES, describe concisely: [different findings should be separated by either a (;) or a (/)]

Tipo di dati

text

Date of Assessment
Descrizione

Date of Assessment

Tipo di dati

date

Skin
Descrizione

Change from Baseline?

Tipo di dati

boolean

Lungs
Descrizione

Change from Baseline?

Tipo di dati

boolean

Cardiovascular
Descrizione

Change from Baseline?

Tipo di dati

boolean

Abdomen (Liver and Spleen)
Descrizione

Change from Baseline?

Tipo di dati

boolean

Vital Signs Follow-Up
Descrizione

Vital Signs Follow-Up

Date
Descrizione

e.g., 01 JAN 10

Tipo di dati

date

Planned Relative Time
Descrizione

e.g., 15 min

Tipo di dati

integer

Actual Time
Descrizione

e.g., 13:02

Tipo di dati

time

Blood Pressure Systolic
Descrizione

Supine

Tipo di dati

integer

Unità di misura
  • mmHg
mmHg
Blood Pressure Diastolic
Descrizione

Supine

Tipo di dati

integer

Unità di misura
  • mmHg
mmHg
Heart rate
Descrizione

Heart rate

Tipo di dati

integer

Unità di misura
  • bpm
bpm
Temperature
Descrizione

oral

Tipo di dati

float

Unità di misura
  • °C
°C
12 LEAD ECG Follow-Up
Descrizione

12 LEAD ECG Follow-Up

Start date of ECG
Descrizione

Start date of ECG

Tipo di dati

date

Planned Relative Time
Descrizione

Planned Relative Time

Tipo di dati

text

Start Time of ECG
Descrizione

Start Time of ECG

Tipo di dati

time

Ventricular Rate
Descrizione

Ventricular Rate

Tipo di dati

integer

Unità di misura
  • bpm
bpm
PR Interval
Descrizione

PR Interval

Tipo di dati

integer

Unità di misura
  • msec
msec
QRS Duration
Descrizione

QRS Duration

Tipo di dati

integer

Unità di misura
  • msec
msec
Uncorrected QT Interval
Descrizione

Uncorrected QT Interval

Tipo di dati

integer

Unità di misura
  • msec
msec
QTc Invertal
Descrizione

QTc Invertal

Tipo di dati

integer

Unità di misura
  • msec
msec
Result of the ECG
Descrizione

Enter code for result from the following list: 1=Normal 2=Abnormal - not clinically significant 3=Abnormal - clinically significant 4=No result (not available)

Tipo di dati

integer

12 LEAD ECG Abnormalities Follow-Up
Descrizione

12 LEAD ECG Abnormalities Follow-Up

Date of ECG
Descrizione

Date of ECG

Tipo di dati

date

Time of ECG
Descrizione

Time of ECG

Tipo di dati

time

Rhythm
Descrizione

Rhythm

Tipo di dati

integer

P-Wave and QRS Morphology
Descrizione

P-Wave and QRS Morphology

Tipo di dati

integer

Conduction
Descrizione

Conduction

Tipo di dati

integer

Myocardial Infraction
Descrizione

Myocardial Infraction

Tipo di dati

integer

Depolarisation/Repolarisation (QRS-T)
Descrizione

Depolarisation/Repolarisation (QRS-T)

Tipo di dati

integer

Other abnormalities
Descrizione

Other abnormalities

Tipo di dati

integer

Electronically transferred laboratory data Follow-Up
Descrizione

Electronically transferred laboratory data Follow-Up

Clinical chemistry
Descrizione

Clinical chemistry

Tipo di dati

datetime

Haematology
Descrizione

Haematology

Tipo di dati

datetime

Urinalisys
Descrizione

Urinalisys

Tipo di dati

datetime

Pharmacogenetic (PGx) Research
Descrizione

Pharmacogenetic (PGx) Research

Consent for PGx Research
Descrizione

Consent for PGx Research

Tipo di dati

text

Has consent been obtained for PGx Research?
Descrizione

Has consent been obtained for PGx Research?

Tipo di dati

boolean

If YES, record the date informed consent obtained for PGx Research
Descrizione

If YES, record the date informed consent obtained for PGx Research

Tipo di dati

date

If NO, choose ONE reason:
Descrizione

If NO, choose ONE reason:

Tipo di dati

text

Sample collection
Descrizione

Sample collection

Tipo di dati

text

Has a Sample been collected for PGx Research?
Descrizione

Has a Sample been collected for PGx Research?

Tipo di dati

boolean

If YES, record a date sample taken
Descrizione

If YES, record a date sample taken

Tipo di dati

date

Withdrawal of consent
Descrizione

Has subject withdrawn consent for PGx Research?

Tipo di dati

boolean

If YES, record the date informed consentwithdrawn for PGx research
Descrizione

If YES, record the date informed consentwithdrawn for PGx research

Tipo di dati

date

Sample destruction
Descrizione

Has a request been made for sample destruction?

Tipo di dati

boolean

If YES, choose one reason:
Descrizione

If YES, choose one reason:

Tipo di dati

text

Concomitant medications Follow-Up
Descrizione

Concomitant medications Follow-Up

Were any concomitant medications taken by the subject during the study?
Descrizione

Were any concomitant medications taken by the subject during the study?

Tipo di dati

boolean

if YES, record each medication on a separate line using Trade Names where possible
Descrizione

if YES, record each medication on a separate line using Trade Names where possible

Tipo di dati

text

Drug name
Descrizione

Trade Name preferred e.g, Aspirin

Tipo di dati

integer

Unit dose
Descrizione

e.g., 200

Tipo di dati

integer

Units
Descrizione

e.g., mg

Tipo di dati

integer

Frequency
Descrizione

e.g., BID

Tipo di dati

integer

Route
Descrizione

e.g., PO

Tipo di dati

integer

Reason for Medication
Descrizione

e.g., Headache

Tipo di dati

text

Start Date
Descrizione

e.g., 31 MAY 08

Tipo di dati

date

Start Time
Descrizione

e.g., 14:10

Tipo di dati

time

Taken prior to Study?
Descrizione

Taken prior to Study?

Tipo di dati

boolean

Stop Date
Descrizione

e.g., 30 MAY 08

Tipo di dati

date

Stop Time
Descrizione

e.g.,23:00

Tipo di dati

time

Ongoing Medication
Descrizione

Ongoing Medication

Tipo di dati

boolean

Non-Serious Adverse Events
Descrizione

Non-Serious Adverse Events

Did the subject experience any non-serious adverse events during the study?
Descrizione

If this is a Serious Adverse Event (SAE), do not complete this form, go to the SAE section and complete the SAE form. If YES record details below

Tipo di dati

boolean

Event
Descrizione

Diagnosis only (if known)Otherwise Sign/Symptom e.g., Headache

Tipo di dati

text

Start Date
Descrizione

e.g., 25 JAN 09

Tipo di dati

date

Start Time
Descrizione

e.g., 13:25

Tipo di dati

time

Outcome
Descrizione

1=Recovered/Resolved 2=Recovering/Resolving 3=Not recovered/not resolved 4=Recovered/Resolved with sequelae e.g., 1

Tipo di dati

integer

End Date
Descrizione

e.g., 27 JAN 09

Tipo di dati

date

End Time
Descrizione

e.g., 10:20

Tipo di dati

time

Frequency
Descrizione

1=Single episode 2=Intermittent e.g., 1

Tipo di dati

integer

Maximum Intensity
Descrizione

1=Mild 2=Moderate 3=Severe X=Not applicable e.g., 1

Tipo di dati

integer

Action taken with Investigational Product(s) as a Result of the Non-Serious AE
Descrizione

1=Investigational product(s) withdrawn 2=Dose reduced 3=Dose increased 4=Dose not changed 5=Dos interrupted X=not applicable e.g., 4

Tipo di dati

integer

Withdrawal
Descrizione

Did the subject withdraw from study as a result of this AE?

Tipo di dati

boolean

Relationship to Investigational Product(s)
Descrizione

Is there a reasonable possibility that the AE may have been caused by the investigational product?

Tipo di dati

boolean

Serious Adverse Events (SAE)
Descrizione

Serious Adverse Events (SAE)

Did the subject experience a SAE during the study?
Descrizione

if YES record details below

Tipo di dati

boolean

SECTION 1
Descrizione

SECTION 1

Tipo di dati

text

Event
Descrizione

Diagnosis only (if known) Otherwise Sign/Symptom e.g., Anaphylaxis

Tipo di dati

text

Start Date
Descrizione

e.g., 25 JAN 09

Tipo di dati

date

Start Time
Descrizione

e.g., 13:25

Tipo di dati

time

Outcome
Descrizione

1=Recovered/Resolved 2=Recovering/Resolving 3=Not recovered/Not resolved 4=Recovered/Resolved with sequelae 5=Fatal e.g., 1

Tipo di dati

integer

End Date
Descrizione

e.g., 27 JAN 09

Tipo di dati

date

End Time
Descrizione

e.g, 10:20

Tipo di dati

time

Maximum Intensity
Descrizione

1=Mild 2=Moderate 3=Severe X=Not applicable

Tipo di dati

integer

Action taken with Investigational Product(s) as a result of the SAE
Descrizione

1=Investigational product(s) withdrawn 2=Dose reduced 3=Dose increased 4=Dose not changed 5=Dose interrupted X=Not applicable

Tipo di dati

integer

Withdrawal
Descrizione

Did the subject withdraw from study as a result of this SAE?

Tipo di dati

boolean

Relationship to Investigational Product(s)
Descrizione

Is there a reasonable possibility that the AE may have been caused by the investigational product?

Tipo di dati

boolean

if FATAL, was a post-mortem/autopsy performed
Descrizione

if YES, summarise findings

Tipo di dati

boolean

SECTION 2
Descrizione

SECTION 2

Tipo di dati

text

Seriousness
Descrizione

specify reason(s) for considering this a SAE, and tick all that apply:

Tipo di dati

text

SECTION 3 Demography Data
Descrizione

SECTION 3 Demography Data

Tipo di dati

text

Date of Birth
Descrizione

Date of Birth

Tipo di dati

date

Sex
Descrizione

Sex

Tipo di dati

text

Weight
Descrizione

Weight

Tipo di dati

float

Unità di misura
  • kg
kg
SECTION 4
Descrizione

SECTION 4

Tipo di dati

text

If investigational product(s) was stopped, did the reported event(s) recur after further investigational product(s) were administered?
Descrizione

If investigational product(s) was stopped, did the reported event(s) recur after further investigational product(s) were administered?

Tipo di dati

text

SECTION 5 Possible causes of SAE other than Investigational Product(s)
Descrizione

mark all that apply:

Tipo di dati

text

SECTION 6 RELEVANT Medical Conditions
Descrizione

SECTION 6 RELEVANT Medical Conditions

Tipo di dati

text

Specify any RELEVANT past or present medical disorders, allergies, surgeries that can help explain the SAE.
Descrizione

Ensure each medical condition recorded in this section is also recorded in the appropriate Medical Condition form

Tipo di dati

text

Date of onset
Descrizione

Date of onset

Tipo di dati

date

Condition Present at Time of the SAE?
Descrizione

Condition Present at Time of the SAE?

Tipo di dati

boolean

If NO, Date of Last Occurrence
Descrizione

If NO, Date of Last Occurrence

Tipo di dati

date

SECTION 7 Other relevant risk factors
Descrizione

Provide any family history or social history (e.g., smoking, alcohol, diet, drug abuse, occupational hazard) relevant to the SAE. Ensure each risk factor recorded in this section is also recorded in the appropriate Medical Conditions form

Tipo di dati

text

SECTION 8 RELEVANT concomitant medications
Descrizione

Include details of any concomitant medication(s) that may help explain the SAE, may have caused the SAE or was used to treat the SAE. Ensure each risk factor recorded in this section is also recorded in the appropriate Medical Conditions form

Tipo di dati

text

Drug Name
Descrizione

Trade Name preferred e.g., Zantac

Tipo di dati

text

Dose
Descrizione

e.g., 150

Tipo di dati

text

Unit
Descrizione

e.g., mg

Tipo di dati

float

Frequency
Descrizione

e.g., BID

Tipo di dati

float

Route
Descrizione

Route

Tipo di dati

text

Taken prior to study?
Descrizione

Taken prior to study?

Tipo di dati

boolean

Start Date
Descrizione

e.g., 25 JAN 09

Tipo di dati

date

Stop Date
Descrizione

27 JAN 09

Tipo di dati

date

Ongoing Medication?
Descrizione

Ongoing Medication?

Tipo di dati

boolean

Reason for Medication
Descrizione

e.g., Gastric ulcer

Tipo di dati

text

SECTION 9 Details of Investigational Product(s)
Descrizione

SECTION 9 Details of Investigational Product(s)

Tipo di dati

text

SECTION 10 Details of RELEVANT assessments
Descrizione

Provide detailsn of any tests or procedures carried out to diagnose or confirm the SAE (e.g., laboratory data with units and normal range) of data for this SAE have not been previously entered, and the CRF includes a page for the test, ensure the data is also entered on the page

Tipo di dati

text

SECTION 11 Narrative Remarks
Descrizione

Provide a brief narrative description of the SAE and details of treatment given

Tipo di dati

text

Investigator's signature
Descrizione

Confirming that the data on the SAE pages are accurate and complete

Tipo di dati

text

Investigator's name (print)
Descrizione

Investigator's name (print)

Tipo di dati

text

Date
Descrizione

Date

Tipo di dati

date

Similar models

Follow-Up Forms

  1. StudyEvent: ODM
    1. Follow-Up Forms
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Physical examination data
Concomitant medications
Item
Concomitant medications
text
Adverse Events
Item
Adverse Events
text
Physical Examination
Item
Physical Examination
text
Date of Assessment
Item
Date of Assessment
date
Skin
Item
Skin
boolean
Lungs
Item
Lungs
boolean
Cardiovascular
Item
Cardiovascular
boolean
Abdomen (Liver and Spleen)
Item
Abdomen (Liver and Spleen)
boolean
Item Group
Vital Signs Follow-Up
Date
Item
Date
date
Item
Planned Relative Time
integer
Code List
Planned Relative Time
CL Item
Follow-Up (1)
Actual Time
Item
Actual Time
time
Blood Pressure Systolic
Item
Blood Pressure Systolic
integer
Blood Pressure Diastolic
Item
Blood Pressure Diastolic
integer
Heart rate
Item
Heart rate
integer
Temperature
Item
Temperature
float
Item Group
12 LEAD ECG Follow-Up
Start date of ECG
Item
Start date of ECG
date
Item
Planned Relative Time
text
Code List
Planned Relative Time
CL Item
ECG 1 Follow UP (1)
CL Item
ECG 2 Unscheduled (2)
CL Item
ECG 3 Unscheduled (3)
Start Time of ECG
Item
Start Time of ECG
time
Ventricular Rate
Item
Ventricular Rate
integer
PR Interval
Item
PR Interval
integer
QRS Duration
Item
QRS Duration
integer
Uncorrected QT Interval
Item
Uncorrected QT Interval
integer
QTc Invertal
Item
QTc Invertal
integer
Result of the ECG
Item
Result of the ECG
integer
Item Group
12 LEAD ECG Abnormalities Follow-Up
Date of ECG
Item
Date of ECG
date
Time of ECG
Item
Time of ECG
time
Item
Rhythm
integer
Code List
Rhythm
CL Item
[A 1] Sinus bradycardia (1)
CL Item
[A21] Sinus bradycardia (heart rate 40-50 beats/min) (2)
CL Item
[A22] Sinus bradycardia (heart rate 30-39 beats/min) (3)
CL Item
[A23] Sinus bradycardia (heart rate < 30 beats/min) (4)
CL Item
[A 3] Sinus pause (5)
CL Item
[A 2] Sinus tachycardia (6)
CL Item
[A 4] Ectropic supraventricular beats (7)
CL Item
[A20] Ectropic supraventricular rythm (8)
CL Item
[A17] Wandering atrial pacemaker (9)
CL Item
[A26] Multifocal atrial tachycardia (Wandering atrial pacemaker with heart rate > 100 beats/min) (10)
CL Item
[A 6] Supraventricular tachycardia (Heart rate > 100 beats/min) (11)
CL Item
[A 7] Atrial flutter (12)
CL Item
[A 8] Atrial fibrillation (13)
CL Item
[A 5] Junctional rhythm (heart rate <100 beats/min) (14)
CL Item
[A25] Junctional rhythm (15)
CL Item
[A24] Junctional tachycardia (heart rate > 100 beats/min) (16)
CL Item
[A 9] Ectopic ventricular beats (17)
Item
P-Wave and QRS Morphology
integer
Code List
P-Wave and QRS Morphology
CL Item
[B 3] right ventricular hypertrophy (1)
CL Item
[B 5] Intraatrial conduction delay (2)
CL Item
[B 7] Poor R wave progression (3)
CL Item
[B 9] Left atrial abnormality (4)
CL Item
[B10] Right atrial abnormality (5)
CL Item
[A12] Ventricular couplets (6)
CL Item
[A13] Bigeminy (7)
CL Item
[A28] Trigeminy (8)
CL Item
[A14] Electrical alternans (9)
CL Item
[A29] R on T phenomenon (10)
CL Item
[A18] Ventricular vebrilation (11)
CL Item
[A19] Indioventricular rhythm (heart rate < 100 bpm) (12)
CL Item
[A10] Sustained ventricular tachycardia (13)
CL Item
[A11] Non-sustained ventricular tachycardia  (14)
CL Item
[A33] Sinus arrhythmia  (15)
CL Item
[A33] Sinus arrhythmia  (15)
CL Item
[A27] Ventricular tachycardia  (16)
CL Item
[A30] Monomorphic ventricular tachycardia  (17)
CL Item
[A15] Torsades de Pointes (Polymorphic ventricular tachycardia with prolonged QT) (18)
CL Item
[A31] Polymorphic (sustained and non-sustained) ventricular tachycardia (19)
CL Item
[A16] Artificial pacemaker  (20)
CL Item
[A35] Atrial premature complex (21)
CL Item
[A99]Other abnormal rhythm  (22)
CL Item
[B16] Late R wave transition (23)
CL Item
[D14] Increased voltage consistent with left ventricular hypertrophy (24)
CL Item
[B99] Other morphology (25)
Item
Conduction
integer
Code List
Conduction
CL Item
[C 1] First degree AV block (PR interval > 200 msec) (1)
CL Item
[C20] Short PR interval (2)
CL Item
[C 2] Second degree AV block (Mobitz type 1) (3)
CL Item
[C 3] Second degree AV block (Mobitz type 2) (4)
CL Item
[C16] 2:1 AV block  (5)
CL Item
[C 4] Third degree AV block (6)
CL Item
[C 5] Left axis deviation (QRS axis more negative than -30°) (7)
CL Item
[C 6] Right axis deviation (QRS axis more positive than +110°) (8)
CL Item
[C 7] Incomplete right bundle branch block (9)
CL Item
[C13] Incomplete left bundle branch block (10)
CL Item
[C 8] Right bundle branch block  (11)
CL Item
[C 14] Left anterior hemiblock (synonymous to left anterior fascicular block) (12)
Item
Myocardial Infraction
integer
Code List
Myocardial Infraction
CL Item
[D 1] Myocardial infraction, old (1)
CL Item
[D 2] Myocardial infraction, anterior (2)
CL Item
[D 3] Myocardial infraction, lateral (3)
CL Item
[D 4] Myocardial infraction, posterior (4)
CL Item
[D 5] Myocardial infraction, inferior (5)
Item
Depolarisation/Repolarisation (QRS-T)
integer
Code List
Depolarisation/Repolarisation (QRS-T)
CL Item
[D 7] Non-specific ST-T changes (1)
CL Item
[D19] J point elevation (2)
CL Item
[D 8] ST elevation (3)
CL Item
[D21] ST elevation-pericarditis (4)
CL Item
[D 9] ST depression (5)
CL Item
[D96] ST segment abnormality, not specified (6)
CL Item
[D10] U waves abnormal (7)
CL Item
[D11] T wave inversion (8)
CL Item
[D12] T wave peaked (9)
Item
Other abnormalities
integer
Code List
Other abnormalities
CL Item
[E99] Other abnormalities (1)
CL Item
[C15] Left posterior hemiblock (synonymous to left posterior fascicular block) (2)
CL Item
[C 9] Left bundle branch block  (3)
CL Item
[C17] Bifascicular block (4)
CL Item
[C10] Non-specific intraventricular conduction delay (QRS>120msec) (5)
CL Item
[C11] Accessory pathway (Wolff-Parkinson White, Lown-Ganong-Levine) (6)
CL Item
[C18] AV dissociation  (7)
CL Item
[C28] Prolonged QT 450-500 (8)
CL Item
[C29] Prolonged QT >500 (9)
CL Item
[C30] Prolonged QTc Interval 450-500 (10)
CL Item
[C31] Prolonged QTc Interval >500 (11)
CL Item
[C99] Other conduction (12)
CL Item
[D 6] Myocardial infraction, septal (13)
CL Item
[D20] Myocardial infraction, Non-Q wave (14)
CL Item
[D08] Other myocardial infraction (15)
CL Item
[D15] T waves flat (16)
CL Item
[D16] T waves biphasic (17)
CL Item
[D18] Notched T-waves (18)
CL Item
[D13] Low QRS voltage (19)
CL Item
[D17] T-wave flattening/inversion (20)
CL Item
[D22] Juvenile T wave pattern, early repolarization (21)
CL Item
[D97] T wave abnormality, not specified (22)
CL Item
[D99] Other depolarization/repolarization (23)
Item Group
Electronically transferred laboratory data Follow-Up
Clinical chemistry
Item
Clinical chemistry
datetime
Haematology
Item
Haematology
datetime
Urinalisys
Item
Urinalisys
datetime
Item Group
Pharmacogenetic (PGx) Research
Consent for PGx Research
Item
Consent for PGx Research
text
Has consent been obtained for PGx Research?
Item
Has consent been obtained for PGx Research?
boolean
If YES, record the date informed consent obtained for PGx Research
Item
If YES, record the date informed consent obtained for PGx Research
date
Item
If NO, choose ONE reason:
text
Code List
If NO, choose ONE reason:
CL Item
Subject declined (1)
CL Item
Subject not asked by Investigator (2)
CL Item
Other, specify_______________ (3)
Sample collection
Item
Sample collection
text
Has a Sample been collected for PGx Research?
Item
Has a Sample been collected for PGx Research?
boolean
If YES, record a date sample taken
Item
If YES, record a date sample taken
date
Withdrawal of consent
Item
Withdrawal of consent
boolean
If YES, record the date informed consentwithdrawn for PGx research
Item
If YES, record the date informed consentwithdrawn for PGx research
date
Sample destruction
Item
Sample destruction
boolean
Item
If YES, choose one reason:
text
Code List
If YES, choose one reason:
CL Item
[1] Subject requested (1)
CL Item
[z] Other, specify_____________ (2)
Item Group
Concomitant medications Follow-Up
Were any concomitant medications taken by the subject during the study?
Item
Were any concomitant medications taken by the subject during the study?
boolean
if YES, record each medication on a separate line using Trade Names where possible
Item
if YES, record each medication on a separate line using Trade Names where possible
text
Drug name
Item
Drug name
integer
Unit dose
Item
Unit dose
integer
Units
Item
Units
integer
Frequency
Item
Frequency
integer
Route
Item
Route
integer
Reason for Medication
Item
Reason for Medication
text
Start Date
Item
Start Date
date
Start Time
Item
Start Time
time
Taken prior to Study?
Item
Taken prior to Study?
boolean
Stop Date
Item
Stop Date
date
Stop Time
Item
Stop Time
time
Ongoing Medication
Item
Ongoing Medication
boolean
Item Group
Non-Serious Adverse Events
Did the subject experience any non-serious adverse events during the study?
Item
Did the subject experience any non-serious adverse events during the study?
boolean
Event
Item
Event
text
Start Date
Item
Start Date
date
Start Time
Item
Start Time
time
Outcome
Item
Outcome
integer
End Date
Item
End Date
date
End Time
Item
End Time
time
Frequency
Item
Frequency
integer
Maximum Intensity
Item
Maximum Intensity
integer
Action taken with Investigational Product(s) as a Result of the Non-Serious AE
Item
Action taken with Investigational Product(s) as a Result of the Non-Serious AE
integer
Withdrawal
Item
Withdrawal
boolean
Relationship to Investigational Product(s)
Item
Relationship to Investigational Product(s)
boolean
Item Group
Serious Adverse Events (SAE)
Did the subject experience a SAE during the study?
Item
Did the subject experience a SAE during the study?
boolean
SECTION 1
Item
SECTION 1
text
Event
Item
Event
text
Start Date
Item
Start Date
date
Start Time
Item
Start Time
time
Outcome
Item
Outcome
integer
End Date
Item
End Date
date
End Time
Item
End Time
time
Maximum Intensity
Item
Maximum Intensity
integer
Action taken with Investigational Product(s) as a result of the SAE
Item
Action taken with Investigational Product(s) as a result of the SAE
integer
Withdrawal
Item
Withdrawal
boolean
Relationship to Investigational Product(s)
Item
Relationship to Investigational Product(s)
boolean
if FATAL, was a post-mortem/autopsy performed
Item
if FATAL, was a post-mortem/autopsy performed
boolean
SECTION 2
Item
SECTION 2
text
Item
Seriousness
text
Code List
Seriousness
CL Item
Results in death (1)
CL Item
Is life-threatening (2)
CL Item
Requires hospitalisation or prolongation of existing hospitalisation (3)
CL Item
Results in disability/incapacity (4)
CL Item
Congenital anomaly/birth defect (5)
CL Item
Other, specify______________________________ (6)
CL Item
Liver injury and impaired liver function (7)
SECTION 3 Demography Data
Item
SECTION 3 Demography Data
text
Date of Birth
Item
Date of Birth
date
Item
Sex
text
Code List
Sex
CL Item
Male (1)
CL Item
Female (2)
Weight
Item
Weight
float
SECTION 4
Item
SECTION 4
text
Item
If investigational product(s) was stopped, did the reported event(s) recur after further investigational product(s) were administered?
text
Code List
If investigational product(s) was stopped, did the reported event(s) recur after further investigational product(s) were administered?
CL Item
Yes (1)
CL Item
No (2)
CL Item
Unknown at this time (3)
CL Item
Not applicable (4)
Item
SECTION 5 Possible causes of SAE other than Investigational Product(s)
text
Code List
SECTION 5 Possible causes of SAE other than Investigational Product(s)
CL Item
Disease under study (1)
CL Item
Medical condition(s) specify______________________ (2)
CL Item
Lack of efficacy (3)
CL Item
Withdrawal of investigational product(s) (4)
CL Item
Concomitant medication(s) specify________________ (5)
CL Item
Activity related to study participation (e.g., procedures) (6)
CL Item
Other, specify ________________________________ (7)
SECTION 6 RELEVANT Medical Conditions
Item
SECTION 6 RELEVANT Medical Conditions
text
Specify any RELEVANT past or present medical disorders, allergies, surgeries that can help explain the SAE.
Item
Specify any RELEVANT past or present medical disorders, allergies, surgeries that can help explain the SAE.
text
Date of onset
Item
Date of onset
date
Condition Present at Time of the SAE?
Item
Condition Present at Time of the SAE?
boolean
If NO, Date of Last Occurrence
Item
If NO, Date of Last Occurrence
date
SECTION 7 Other relevant risk factors
Item
SECTION 7 Other relevant risk factors
text
SECTION 8 RELEVANT concomitant medications
Item
SECTION 8 RELEVANT concomitant medications
text
Drug Name
Item
Drug Name
text
Dose
Item
Dose
text
Unit
Item
Unit
float
Frequency
Item
Frequency
float
Route
Item
Route
text
Taken prior to study?
Item
Taken prior to study?
boolean
Start Date
Item
Start Date
date
Stop Date
Item
Stop Date
date
Ongoing Medication?
Item
Ongoing Medication?
boolean
Reason for Medication
Item
Reason for Medication
text
SECTION 9 Details of Investigational Product(s)
Item
SECTION 9 Details of Investigational Product(s)
text
SECTION 10 Details of RELEVANT assessments
Item
SECTION 10 Details of RELEVANT assessments
text
SECTION 11 Narrative Remarks
Item
SECTION 11 Narrative Remarks
text
Investigator's signature
Item
Investigator's signature
text
Investigator's name (print)
Item
Investigator's name (print)
text
Date
Item
Date
date

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial